The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases
Aytekin, A.; Ciltas, A.; Sahinli, H.; Benekli, M.
Journal of BUON Official Journal of the Balkan Union of Oncology 21(1): 281-282
2016
ISSN/ISBN: 1107-0625 PMID: 27061562 Document Number: 688133
Document emailed within 1 workday
Related Documents
2016: (S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma Oncology 30 SupplShepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Flickinger, J.C. 2000: Radiosurgery of brain metastases from renal cell carcinoma: how can you improve on results like this? Cancer Journal 6(6): 360-361
Jensen, R.L.; Shrieve, A.F.; Samlowski, W.; Shrieve, D.C. 2008: Outcomes of patients with brain metastases from melanoma and renal cell carcinoma after primary stereotactic radiosurgery Clinical Neurosurgery 55: 150-159
Sotiropoulos, G.C.; Lang, H.; Liu, C.; Brokalaki, E.I.; Molmenti, E.; Broelsch, C.E. 2005: Surgical treatment of pancreatic metastases of renal cell carcinoma Jop: Journal of the Pancreas 6(4): 339-343
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Mosele, G.R.; Caggiari, G.; Scarpa, R.M.; Doria, C. 2017: The treatment of vertebral metastases from renal cell carcinoma: a retrospective study Minerva Urologica e Nefrologica 69(2): 166-172
Dürr, H.R.; Maier, M.; Pfahler, M.; Baur, A.; Refior, H.J. 1999: Surgical treatment of osseous metastases in patients with renal cell carcinoma Clinical Orthopaedics and Related Research 367: 283-290
Stankard, C.E.; Karl, R.C. 1992: The treatment of isolated pancreatic metastases from renal cell carcinoma: a surgical review American Journal of Gastroenterology 87(11): 1658-1660
Xu, J.; Cao, H. 2013: Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors Zhonghua Wei Chang Wai Ke Za Zhi 16(3): 288-291
Ruggeri, B.A.; Miknyoczki, S.J.; Singh, J.; Hudkins, R.L. 1999: Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models Current Medicinal Chemistry 6(9): 845-857
Durocher, Y.; Chapdelaine, A.; Chevalier, S. 1989: Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145 Cancer Research 49(17): 4818-4823
Eto, M. 2017: New Treatment Options for Renal Cell Carcinoma - Efficacy and Safety of Immune Checkpoint Inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(8): 667-673
Miyata, H.; Sasaki, T.; Kuwahara, K.; Serikawa, M.; Chayama, K. 2006: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines International Journal of Oncology 28(4): 915-921
Goldman, J. 2004: CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology 10(3): 181-184
Muhammet Hacioglu, B.; Kostek, O.; Erdogan, B.; Uzunoglu, S.; Cicin, I. 2017: Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis Journal of Buon: Official Journal of the Balkan Union of Oncology 22(3): 586-591
Pang, S.H.; Guo, Z.R.; Liang, X.T. 1997: Synthesis and biological activity of tyrosine protein kinase inhibitors Yao Xue Xue Bao 32(7): 515-523
Przytulska, J.; Tupikowski, K.; Bednarek-Tupikowska, G. 2014: Thyroid dysfunction in patients treated with tyrosine kinase inhibitors Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 36(211): 42-44
Zhao, L.-d.; Li, J.-L.; Wang, Y.; Wang, B.; Wang, H.-Y.; Hao, X.-Z.; Cui, C.-X.; Zhang, X.-R.; Shi, Y.-K. 2011: Analysis of chemotherapeutic efficacy after a failed regimen of epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small cell lung carcinoma Zhonghua Yi Xue Za Zhi 91(6): 366-369
Kato, T.; Sato, K.; Abe, R.; Moriyama, M. 1989: The role of embolization/chemoembolization in the treatment of renal cell carcinoma Progress in Clinical and Biological Research 303: 697-705